← All Cytosorbents CORP filings

Cytosorbents CORP 10-Q quarterly reports

Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.

NASDAQ
CTSO
Cytosorbents CORP
10-Q: CytoSorbents Q3 2025: Reduced Loss, Strategic Restructuring
CytoSorbents Corporation reported a significantly reduced net loss for the nine months ended September 30, 2025, driven by revenue growth and cost reductions, despite regulatory setbacks for DrugSorb-ATR and Nasdaq compliance concerns.
NASDAQ
CTSO
Cytosorbents CORP
10-Q: CytoSorbents Q2 2025: Revenue Up, Regulatory Hurdles Mount
CytoSorbents Corporation reports increased revenue and improved operating loss in Q2 2025, but faces significant regulatory setbacks for DrugSorb-ATR in the U.S. and Canada, raising going concern doubts.
NASDAQ
CTSO
Cytosorbents CORP
10-Q: CytoSorbents Reports Q1 2025 Results, Revenue Declines Slightly Amid Strategic Realignment
CytoSorbents' Q1 2025 revenue dipped slightly, but the company is optimistic about future growth following strategic changes and potential regulatory approvals.
NASDAQ
CTSO
Cytosorbents CORP
10-Q: CytoSorbents Reports Q3 2024 Results: Revenue Up, Losses Narrow Amidst Strategic Shifts
CytoSorbents Corporation saw a revenue increase in Q3 2024, while also experiencing a reduction in net losses compared to the same period last year.
NASDAQ
CTSO
Cytosorbents CORP
10-Q: CytoSorbents Reports Q2 2024 Results, Secures $20 Million Debt Financing
CytoSorbents Corporation announced its second quarter 2024 financial results, highlighted by a new $20 million debt facility and progress in clinical trials.
NASDAQ
CTSO
Cytosorbents CORP
10-Q: CytoSorbents Corporation Reports First Quarter 2024 Results, Cites Progress in Clinical Trials and Sales Growth
CytoSorbents Corporation announced its first quarter 2024 financial results, highlighting a revenue increase in product sales and progress in clinical trials, while also noting ongoing financial challenges.